SlideShare uma empresa Scribd logo
1 de 17
Baixar para ler offline
www.CancerSupportCommunity.org Uniting The Wellness Community and Gilda’s Club Worldwide
Working with Regulators: A Focus on CMS
An Educational Program of the
Cancer Policy Institute at the Cancer Support Community
in Partnership with Uniting a Community (UaC):
Policy, Advocacy, Education and Action Network
Medicare’s
National Coverage Determination
Process
http://www.cms.gov/medicare-coverage-database/
NCD Definitions in SSA
1862(l)(6) National and local coverage
determination defined.—For purposes of this
subsection—
(A) National coverage determination.—The term
“national coverage determination” means a
determination by the Secretary with respect to
whether or not a particular item or service is
covered nationally under this title
What is a Covered Service?
• which, if subject to FDA review, has been
approved or cleared for at least one indication;
• which falls within a Medicare Benefit Category
(generally found in §1861 of the Act);
• which is not statutorily excluded based on
§1862(a)(2)-(15) of the Act;
• which is reasonable and necessary based on
§1862(a)(1)
Generally, an item or service:
Reasonable & Necessary
• Sufficient level of confidence that the
evidence is adequate to conclude that the
item or service:
– Improves health outcomes
– Is generalizable to the Medicare population
– Is generalizable to general provider community
PATIENT
Usual Workup
Usual Therapy
Usual Outcome
Workup + New Test
Different Therapy
Better Outcome
Worse Outcome
The Preferred Road to Diagnostic
and Therapeutic Coverage
Diagnostic
 Provide adequate evidence
that
 The incremental information
obtained by new diagnostic
technology compared to
alternatives
 Changes physician
recommendations
 Resulting in changes in therapy
 That improve clinically
meaningful health outcomes
 In Medicare beneficiaries
Therapeutic
 Provide adequate
evidence that
 The new therapeutic
intervention compared to
alternatives
 Results in improve
clinically meaningful
health outcomes
• In Medicare beneficiaries
Health Outcomes of Interest
• Longer life and improved
function/participation
• Longer life with arrested
decline
• Significant symptom
improvement allowing better
function/participation
• Reduced need for
burdensome tests and
treatments
• Longer life with declining
function/participation
• Improved disease-specific
survival without improved
overall survival
• Surrogate test result better
• Image looks better
• Doctor feels confident
More Impressive Less Impressive
Medicare has stated publicly that as a matter of policy that it does not generally
consider cost in making national coverage determinations.
What prompts NCDs?
• External request (statutory)
– Current national non-coverage policy
– Substantial LCD variation
• Internally generated
– Extensive literature or important new
study
– Technological advance with potential
major clinical or economic impact
– Major concerns about inappropriate use
NCD Process
• Formal Request (30 day comment period)
• Benefit Category Determination
• Review of evidence by CMS
• Technology Assessment/MEDCAC
• Proposed Determination (30 day comment
period)
• Final Determination posted on CMS Web site
60 days later
10
MEDICARE NATIONAL COVERAGE PROCESS
Staff Review
Proposed
Decision
Memorandum
Posted
National
Coverage
Request
MEDCAC
External
Technology
Assessment
6 months
Reconsideration
Staff Review
Public
Comment
Final Decision
Memorandum
and
Implementation
Instructions
30 days 60 days
9 months
Preliminary
Discussions
Benefit
Category
Departmental
Appeals Board
12
Evidence for NCDs
• Medical Literature
Peer Reviewed Journal
Medical texts
• Technology Assessments thru AHRQ
Evidence Based Practice Centers
• Medicare Evidence Development and Coverage
Advisory Committee (MEDCAC)
MEDCAC
Medicare Evidence Development Coverage Advisory
Committee
• Meets on controversial issues
• Votes only on the quality of the evidence
and not on a coverage determination
• Not necessarily on NCDs
– Usual Care of Chronic Wounds 2006
14
Evidence Deficits
• No evidence
• Standard measures missing
• Short term follow-up to studies
• Lack of comparative effectiveness
• Generalizability for Medicare beneficiaries
National Coverage Determinations
• National Coverage
• National Non-Coverage
• National Coverage with Limitations
• Contractor Discretion
Reconsideration of NCD
• An NCD Reconsideration may be requested when:
An NCD currently exists, any individual or entity may request that we
reconsider any provision of that NCD by filing an acceptable request for an
NCD reconsideration.
1) Additional material medical and/or scientific information that was not
considered during the initial review, that is, results from new clinical trials,
new scientific or medical publications, or studies supporting the request
1) Arguments that our conclusion materially misinterpreted the existing
evidence at the time the NCD was made.
www.CancerSupportCommunity.org Uniting The Wellness Community and Gilda’s Club Worldwide
Working with Regulators: A Focus on CMS
was made possible thanks to the support of GlaxoSmithKline

Mais conteúdo relacionado

Mais procurados

Advances in Rare Disease Gareth Baynam, Western Australia Health Department (...
Advances in Rare Disease Gareth Baynam, Western Australia Health Department (...Advances in Rare Disease Gareth Baynam, Western Australia Health Department (...
Advances in Rare Disease Gareth Baynam, Western Australia Health Department (...Canadian Organization for Rare Disorders
 
Evidence-Based Clinical Practice Guidelines for Physical and Rehabiliatation ...
Evidence-Based Clinical Practice Guidelines for Physical and Rehabiliatation ...Evidence-Based Clinical Practice Guidelines for Physical and Rehabiliatation ...
Evidence-Based Clinical Practice Guidelines for Physical and Rehabiliatation ...Yasser Sami Abdel Dayem Amer
 
Patient Centered Care | Unit 2a Lecture
Patient Centered Care | Unit 2a LecturePatient Centered Care | Unit 2a Lecture
Patient Centered Care | Unit 2a LectureCMDLMS
 
DoC - Helen Maitland presentation
DoC - Helen Maitland presentationDoC - Helen Maitland presentation
DoC - Helen Maitland presentation6EAScot
 
Cadth 2015 c1 chelak cadth tr_ process_cadth symposium_2015_finalapril13
Cadth 2015 c1 chelak cadth tr_ process_cadth symposium_2015_finalapril13Cadth 2015 c1 chelak cadth tr_ process_cadth symposium_2015_finalapril13
Cadth 2015 c1 chelak cadth tr_ process_cadth symposium_2015_finalapril13CADTH Symposium
 
Richard Scott - Cambridge Rare Disease Summit 2015
Richard Scott - Cambridge Rare Disease Summit 2015Richard Scott - Cambridge Rare Disease Summit 2015
Richard Scott - Cambridge Rare Disease Summit 2015CamRARE Disease Network
 
Systematic Review of CoPs in surgery
Systematic Review of CoPs in surgerySystematic Review of CoPs in surgery
Systematic Review of CoPs in surgeryegoubanova
 
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...Canadian Organization for Rare Disorders
 
Ian Graham Regenstrief Conference Slides October 4 2007
Ian Graham  Regenstrief Conference Slides October 4 2007Ian Graham  Regenstrief Conference Slides October 4 2007
Ian Graham Regenstrief Conference Slides October 4 2007ShawnHoke
 
Customized Patient Care through Patient Support Programs for Rare/Orphan Drugs
Customized Patient Care through Patient Support Programs for Rare/Orphan DrugsCustomized Patient Care through Patient Support Programs for Rare/Orphan Drugs
Customized Patient Care through Patient Support Programs for Rare/Orphan DrugsCanadian Organization for Rare Disorders
 

Mais procurados (20)

Dr. Thombs: Rare Disease Day 2016 Conference
Dr. Thombs: Rare Disease Day 2016 Conference Dr. Thombs: Rare Disease Day 2016 Conference
Dr. Thombs: Rare Disease Day 2016 Conference
 
Advances in Rare Disease Gareth Baynam, Western Australia Health Department (...
Advances in Rare Disease Gareth Baynam, Western Australia Health Department (...Advances in Rare Disease Gareth Baynam, Western Australia Health Department (...
Advances in Rare Disease Gareth Baynam, Western Australia Health Department (...
 
Evidence-Based Clinical Practice Guidelines for Physical and Rehabiliatation ...
Evidence-Based Clinical Practice Guidelines for Physical and Rehabiliatation ...Evidence-Based Clinical Practice Guidelines for Physical and Rehabiliatation ...
Evidence-Based Clinical Practice Guidelines for Physical and Rehabiliatation ...
 
Patient Centered Care | Unit 2a Lecture
Patient Centered Care | Unit 2a LecturePatient Centered Care | Unit 2a Lecture
Patient Centered Care | Unit 2a Lecture
 
DoC - Helen Maitland presentation
DoC - Helen Maitland presentationDoC - Helen Maitland presentation
DoC - Helen Maitland presentation
 
Hta barriers to ideal
Hta barriers to idealHta barriers to ideal
Hta barriers to ideal
 
Cadth 2015 c1 chelak cadth tr_ process_cadth symposium_2015_finalapril13
Cadth 2015 c1 chelak cadth tr_ process_cadth symposium_2015_finalapril13Cadth 2015 c1 chelak cadth tr_ process_cadth symposium_2015_finalapril13
Cadth 2015 c1 chelak cadth tr_ process_cadth symposium_2015_finalapril13
 
Richard Scott - Cambridge Rare Disease Summit 2015
Richard Scott - Cambridge Rare Disease Summit 2015Richard Scott - Cambridge Rare Disease Summit 2015
Richard Scott - Cambridge Rare Disease Summit 2015
 
Systematic Review of CoPs in surgery
Systematic Review of CoPs in surgerySystematic Review of CoPs in surgery
Systematic Review of CoPs in surgery
 
David page cord standards of care 05 03-2015
David page cord standards of  care 05 03-2015David page cord standards of  care 05 03-2015
David page cord standards of care 05 03-2015
 
Aaron S. Kesselheim, Prescription Drug Prices and "Value"
Aaron S. Kesselheim, Prescription Drug Prices and "Value"Aaron S. Kesselheim, Prescription Drug Prices and "Value"
Aaron S. Kesselheim, Prescription Drug Prices and "Value"
 
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
 
Ian Graham Regenstrief Conference Slides October 4 2007
Ian Graham  Regenstrief Conference Slides October 4 2007Ian Graham  Regenstrief Conference Slides October 4 2007
Ian Graham Regenstrief Conference Slides October 4 2007
 
Ira Klein, Can Value-based Contracting Work for Pharma Companies?
Ira Klein, Can Value-based Contracting Work for Pharma Companies?Ira Klein, Can Value-based Contracting Work for Pharma Companies?
Ira Klein, Can Value-based Contracting Work for Pharma Companies?
 
The Scleroderma Patient-centered Intervention Network: SPIN
The Scleroderma Patient-centered  Intervention Network: SPINThe Scleroderma Patient-centered  Intervention Network: SPIN
The Scleroderma Patient-centered Intervention Network: SPIN
 
STREAM THREE: Jeff Keefer, Inclusion in Clinical Trials
STREAM THREE: Jeff Keefer, Inclusion in Clinical Trials STREAM THREE: Jeff Keefer, Inclusion in Clinical Trials
STREAM THREE: Jeff Keefer, Inclusion in Clinical Trials
 
Customized Patient Care through Patient Support Programs for Rare/Orphan Drugs
Customized Patient Care through Patient Support Programs for Rare/Orphan DrugsCustomized Patient Care through Patient Support Programs for Rare/Orphan Drugs
Customized Patient Care through Patient Support Programs for Rare/Orphan Drugs
 
Day 2: CORD 2021 Fall Conference Slides
Day 2: CORD 2021 Fall Conference SlidesDay 2: CORD 2021 Fall Conference Slides
Day 2: CORD 2021 Fall Conference Slides
 
Julian Little & Beth Potter: Rare Disease Day 2016 Conference
Julian Little & Beth Potter: Rare Disease Day 2016 Conference Julian Little & Beth Potter: Rare Disease Day 2016 Conference
Julian Little & Beth Potter: Rare Disease Day 2016 Conference
 
Chander slides november 19 20 2015-toronto
Chander slides november 19 20 2015-torontoChander slides november 19 20 2015-toronto
Chander slides november 19 20 2015-toronto
 

Semelhante a James Rollins' Presentation

Update on Cancer Meds Review and Approval 23Mar2023.pptx
Update on Cancer Meds Review and Approval 23Mar2023.pptxUpdate on Cancer Meds Review and Approval 23Mar2023.pptx
Update on Cancer Meds Review and Approval 23Mar2023.pptxCCSNCommunication
 
Working with Regulators: A Focus on CMS | June 24, 2014 | All Slides
Working with Regulators: A Focus on CMS | June 24, 2014 | All SlidesWorking with Regulators: A Focus on CMS | June 24, 2014 | All Slides
Working with Regulators: A Focus on CMS | June 24, 2014 | All SlidesCancerSupportComm
 
Rx16 tpp tues_1230_1_worthy_2williams
Rx16 tpp tues_1230_1_worthy_2williamsRx16 tpp tues_1230_1_worthy_2williams
Rx16 tpp tues_1230_1_worthy_2williamsOPUNITE
 
How patient groups can have more say in the drug approval process
How patient groups can have more say in the drug approval processHow patient groups can have more say in the drug approval process
How patient groups can have more say in the drug approval processCanadian Cancer Survivor Network
 
UC BRAID Clinical Research Billing
UC BRAID Clinical Research BillingUC BRAID Clinical Research Billing
UC BRAID Clinical Research BillingCTSI at UCSF
 
Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...Dr. Tayaba Khan
 
An Insider's Guide to Working with CMS - Shari Ling
An Insider's Guide to Working with CMS - Shari LingAn Insider's Guide to Working with CMS - Shari Ling
An Insider's Guide to Working with CMS - Shari LingCancerSupportComm
 
David-Graham-HGML-presentation-20190424.pptx
David-Graham-HGML-presentation-20190424.pptxDavid-Graham-HGML-presentation-20190424.pptx
David-Graham-HGML-presentation-20190424.pptxssusera155d8
 
David-Graham-HGML-presentation-20190424.pptx
David-Graham-HGML-presentation-20190424.pptxDavid-Graham-HGML-presentation-20190424.pptx
David-Graham-HGML-presentation-20190424.pptxssuser660bb1
 
David-Graham-HGML-presentation-20190424.pptx
David-Graham-HGML-presentation-20190424.pptxDavid-Graham-HGML-presentation-20190424.pptx
David-Graham-HGML-presentation-20190424.pptxssusera155d8
 
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...Nathan White, CPC
 
How Timely is Canada’s Medication Review and Approval Process?
How Timely is Canada’s Medication Review and Approval Process?How Timely is Canada’s Medication Review and Approval Process?
How Timely is Canada’s Medication Review and Approval Process?Canadian Cancer Survivor Network
 
The Pathway to Accountable Care
The Pathway to Accountable CareThe Pathway to Accountable Care
The Pathway to Accountable Careseprogram
 
Digital Scholar Webinar: Clinicaltrials.gov Registration and Reporting Documents
Digital Scholar Webinar: Clinicaltrials.gov Registration and Reporting DocumentsDigital Scholar Webinar: Clinicaltrials.gov Registration and Reporting Documents
Digital Scholar Webinar: Clinicaltrials.gov Registration and Reporting DocumentsSC CTSI at USC and CHLA
 
SAFTINet Overview for EDRC
SAFTINet Overview for EDRCSAFTINet Overview for EDRC
SAFTINet Overview for EDRCMarion Sills
 

Semelhante a James Rollins' Presentation (20)

Update on Cancer Meds Review and Approval 23Mar2023.pptx
Update on Cancer Meds Review and Approval 23Mar2023.pptxUpdate on Cancer Meds Review and Approval 23Mar2023.pptx
Update on Cancer Meds Review and Approval 23Mar2023.pptx
 
Update on Cancer Meds Review and Approval 23Mar2023.pptx
Update on Cancer Meds Review and Approval 23Mar2023.pptxUpdate on Cancer Meds Review and Approval 23Mar2023.pptx
Update on Cancer Meds Review and Approval 23Mar2023.pptx
 
Working with Regulators: A Focus on CMS | June 24, 2014 | All Slides
Working with Regulators: A Focus on CMS | June 24, 2014 | All SlidesWorking with Regulators: A Focus on CMS | June 24, 2014 | All Slides
Working with Regulators: A Focus on CMS | June 24, 2014 | All Slides
 
RWD/RWE for Rare Disease Drugs Webinar
RWD/RWE for Rare Disease Drugs WebinarRWD/RWE for Rare Disease Drugs Webinar
RWD/RWE for Rare Disease Drugs Webinar
 
Rx16 tpp tues_1230_1_worthy_2williams
Rx16 tpp tues_1230_1_worthy_2williamsRx16 tpp tues_1230_1_worthy_2williams
Rx16 tpp tues_1230_1_worthy_2williams
 
Regulation reimbursement and evidence on NMT
Regulation reimbursement and evidence on NMTRegulation reimbursement and evidence on NMT
Regulation reimbursement and evidence on NMT
 
How patient groups can have more say in the drug approval process
How patient groups can have more say in the drug approval processHow patient groups can have more say in the drug approval process
How patient groups can have more say in the drug approval process
 
RDD 2020 Day 1 PM: Health Canada Regulatory Update
RDD 2020 Day 1 PM: Health Canada Regulatory UpdateRDD 2020 Day 1 PM: Health Canada Regulatory Update
RDD 2020 Day 1 PM: Health Canada Regulatory Update
 
UC BRAID Clinical Research Billing
UC BRAID Clinical Research BillingUC BRAID Clinical Research Billing
UC BRAID Clinical Research Billing
 
Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...
 
An Insider's Guide to Working with CMS - Shari Ling
An Insider's Guide to Working with CMS - Shari LingAn Insider's Guide to Working with CMS - Shari Ling
An Insider's Guide to Working with CMS - Shari Ling
 
David-Graham-HGML-presentation-20190424.pptx
David-Graham-HGML-presentation-20190424.pptxDavid-Graham-HGML-presentation-20190424.pptx
David-Graham-HGML-presentation-20190424.pptx
 
David-Graham-HGML-presentation-20190424.pptx
David-Graham-HGML-presentation-20190424.pptxDavid-Graham-HGML-presentation-20190424.pptx
David-Graham-HGML-presentation-20190424.pptx
 
David-Graham-HGML-presentation-20190424.pptx
David-Graham-HGML-presentation-20190424.pptxDavid-Graham-HGML-presentation-20190424.pptx
David-Graham-HGML-presentation-20190424.pptx
 
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
 
Drug Approval & Reimbursement Processes
Drug Approval & Reimbursement ProcessesDrug Approval & Reimbursement Processes
Drug Approval & Reimbursement Processes
 
How Timely is Canada’s Medication Review and Approval Process?
How Timely is Canada’s Medication Review and Approval Process?How Timely is Canada’s Medication Review and Approval Process?
How Timely is Canada’s Medication Review and Approval Process?
 
The Pathway to Accountable Care
The Pathway to Accountable CareThe Pathway to Accountable Care
The Pathway to Accountable Care
 
Digital Scholar Webinar: Clinicaltrials.gov Registration and Reporting Documents
Digital Scholar Webinar: Clinicaltrials.gov Registration and Reporting DocumentsDigital Scholar Webinar: Clinicaltrials.gov Registration and Reporting Documents
Digital Scholar Webinar: Clinicaltrials.gov Registration and Reporting Documents
 
SAFTINet Overview for EDRC
SAFTINet Overview for EDRCSAFTINet Overview for EDRC
SAFTINet Overview for EDRC
 

Último

Ahmedabad Call Girls CG Road 🔝9907093804 Short 1500 💋 Night 6000
Ahmedabad Call Girls CG Road 🔝9907093804  Short 1500  💋 Night 6000Ahmedabad Call Girls CG Road 🔝9907093804  Short 1500  💋 Night 6000
Ahmedabad Call Girls CG Road 🔝9907093804 Short 1500 💋 Night 6000aliya bhat
 
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort ServiceCall Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Serviceparulsinha
 
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...narwatsonia7
 
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Availablenarwatsonia7
 
Asthma Review - GINA guidelines summary 2024
Asthma Review - GINA guidelines summary 2024Asthma Review - GINA guidelines summary 2024
Asthma Review - GINA guidelines summary 2024Gabriel Guevara MD
 
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service Availablenarwatsonia7
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformKweku Zurek
 
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
Call Girls Thane Just Call 9910780858 Get High Class Call Girls ServiceCall Girls Thane Just Call 9910780858 Get High Class Call Girls Service
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Servicesonalikaur4
 
Aspirin presentation slides by Dr. Rewas Ali
Aspirin presentation slides by Dr. Rewas AliAspirin presentation slides by Dr. Rewas Ali
Aspirin presentation slides by Dr. Rewas AliRewAs ALI
 
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...narwatsonia7
 
Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...
Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...
Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...narwatsonia7
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
Call Girls Electronic City Just Call 7001305949 Top Class Call Girl Service A...
Call Girls Electronic City Just Call 7001305949 Top Class Call Girl Service A...Call Girls Electronic City Just Call 7001305949 Top Class Call Girl Service A...
Call Girls Electronic City Just Call 7001305949 Top Class Call Girl Service A...narwatsonia7
 
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...saminamagar
 
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...Miss joya
 
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service LucknowCall Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknownarwatsonia7
 
Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...
Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...
Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...narwatsonia7
 
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment Booking
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment BookingCall Girl Koramangala | 7001305949 At Low Cost Cash Payment Booking
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment Bookingnarwatsonia7
 
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Availablenarwatsonia7
 
Sonagachi Call Girls Services 9907093804 @24x7 High Class Babes Here Call Now
Sonagachi Call Girls Services 9907093804 @24x7 High Class Babes Here Call NowSonagachi Call Girls Services 9907093804 @24x7 High Class Babes Here Call Now
Sonagachi Call Girls Services 9907093804 @24x7 High Class Babes Here Call NowRiya Pathan
 

Último (20)

Ahmedabad Call Girls CG Road 🔝9907093804 Short 1500 💋 Night 6000
Ahmedabad Call Girls CG Road 🔝9907093804  Short 1500  💋 Night 6000Ahmedabad Call Girls CG Road 🔝9907093804  Short 1500  💋 Night 6000
Ahmedabad Call Girls CG Road 🔝9907093804 Short 1500 💋 Night 6000
 
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort ServiceCall Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
 
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
 
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
 
Asthma Review - GINA guidelines summary 2024
Asthma Review - GINA guidelines summary 2024Asthma Review - GINA guidelines summary 2024
Asthma Review - GINA guidelines summary 2024
 
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy Platform
 
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
Call Girls Thane Just Call 9910780858 Get High Class Call Girls ServiceCall Girls Thane Just Call 9910780858 Get High Class Call Girls Service
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
 
Aspirin presentation slides by Dr. Rewas Ali
Aspirin presentation slides by Dr. Rewas AliAspirin presentation slides by Dr. Rewas Ali
Aspirin presentation slides by Dr. Rewas Ali
 
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
 
Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...
Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...
Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
Call Girls Electronic City Just Call 7001305949 Top Class Call Girl Service A...
Call Girls Electronic City Just Call 7001305949 Top Class Call Girl Service A...Call Girls Electronic City Just Call 7001305949 Top Class Call Girl Service A...
Call Girls Electronic City Just Call 7001305949 Top Class Call Girl Service A...
 
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
 
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
 
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service LucknowCall Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
 
Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...
Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...
Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...
 
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment Booking
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment BookingCall Girl Koramangala | 7001305949 At Low Cost Cash Payment Booking
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment Booking
 
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
 
Sonagachi Call Girls Services 9907093804 @24x7 High Class Babes Here Call Now
Sonagachi Call Girls Services 9907093804 @24x7 High Class Babes Here Call NowSonagachi Call Girls Services 9907093804 @24x7 High Class Babes Here Call Now
Sonagachi Call Girls Services 9907093804 @24x7 High Class Babes Here Call Now
 

James Rollins' Presentation

  • 1. www.CancerSupportCommunity.org Uniting The Wellness Community and Gilda’s Club Worldwide Working with Regulators: A Focus on CMS An Educational Program of the Cancer Policy Institute at the Cancer Support Community in Partnership with Uniting a Community (UaC): Policy, Advocacy, Education and Action Network
  • 3. NCD Definitions in SSA 1862(l)(6) National and local coverage determination defined.—For purposes of this subsection— (A) National coverage determination.—The term “national coverage determination” means a determination by the Secretary with respect to whether or not a particular item or service is covered nationally under this title
  • 4. What is a Covered Service? • which, if subject to FDA review, has been approved or cleared for at least one indication; • which falls within a Medicare Benefit Category (generally found in §1861 of the Act); • which is not statutorily excluded based on §1862(a)(2)-(15) of the Act; • which is reasonable and necessary based on §1862(a)(1) Generally, an item or service:
  • 5. Reasonable & Necessary • Sufficient level of confidence that the evidence is adequate to conclude that the item or service: – Improves health outcomes – Is generalizable to the Medicare population – Is generalizable to general provider community
  • 6. PATIENT Usual Workup Usual Therapy Usual Outcome Workup + New Test Different Therapy Better Outcome Worse Outcome
  • 7. The Preferred Road to Diagnostic and Therapeutic Coverage Diagnostic  Provide adequate evidence that  The incremental information obtained by new diagnostic technology compared to alternatives  Changes physician recommendations  Resulting in changes in therapy  That improve clinically meaningful health outcomes  In Medicare beneficiaries Therapeutic  Provide adequate evidence that  The new therapeutic intervention compared to alternatives  Results in improve clinically meaningful health outcomes • In Medicare beneficiaries
  • 8. Health Outcomes of Interest • Longer life and improved function/participation • Longer life with arrested decline • Significant symptom improvement allowing better function/participation • Reduced need for burdensome tests and treatments • Longer life with declining function/participation • Improved disease-specific survival without improved overall survival • Surrogate test result better • Image looks better • Doctor feels confident More Impressive Less Impressive Medicare has stated publicly that as a matter of policy that it does not generally consider cost in making national coverage determinations.
  • 9. What prompts NCDs? • External request (statutory) – Current national non-coverage policy – Substantial LCD variation • Internally generated – Extensive literature or important new study – Technological advance with potential major clinical or economic impact – Major concerns about inappropriate use
  • 10. NCD Process • Formal Request (30 day comment period) • Benefit Category Determination • Review of evidence by CMS • Technology Assessment/MEDCAC • Proposed Determination (30 day comment period) • Final Determination posted on CMS Web site 60 days later 10
  • 11. MEDICARE NATIONAL COVERAGE PROCESS Staff Review Proposed Decision Memorandum Posted National Coverage Request MEDCAC External Technology Assessment 6 months Reconsideration Staff Review Public Comment Final Decision Memorandum and Implementation Instructions 30 days 60 days 9 months Preliminary Discussions Benefit Category Departmental Appeals Board
  • 12. 12 Evidence for NCDs • Medical Literature Peer Reviewed Journal Medical texts • Technology Assessments thru AHRQ Evidence Based Practice Centers • Medicare Evidence Development and Coverage Advisory Committee (MEDCAC)
  • 13. MEDCAC Medicare Evidence Development Coverage Advisory Committee • Meets on controversial issues • Votes only on the quality of the evidence and not on a coverage determination • Not necessarily on NCDs – Usual Care of Chronic Wounds 2006
  • 14. 14 Evidence Deficits • No evidence • Standard measures missing • Short term follow-up to studies • Lack of comparative effectiveness • Generalizability for Medicare beneficiaries
  • 15. National Coverage Determinations • National Coverage • National Non-Coverage • National Coverage with Limitations • Contractor Discretion
  • 16. Reconsideration of NCD • An NCD Reconsideration may be requested when: An NCD currently exists, any individual or entity may request that we reconsider any provision of that NCD by filing an acceptable request for an NCD reconsideration. 1) Additional material medical and/or scientific information that was not considered during the initial review, that is, results from new clinical trials, new scientific or medical publications, or studies supporting the request 1) Arguments that our conclusion materially misinterpreted the existing evidence at the time the NCD was made.
  • 17. www.CancerSupportCommunity.org Uniting The Wellness Community and Gilda’s Club Worldwide Working with Regulators: A Focus on CMS was made possible thanks to the support of GlaxoSmithKline